Form 4: Agenus CEO Opts for Stock-Based Salary, Boosts Holdings

Agenus Inc.'s Chairman and CEO, Garo H. Armen, acquired 3,587 shares of common stock as part of his salary compensation, increasing his direct and indirect beneficial ownership.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 3,587 shares of Agenus common stock.
• The acquisition occurred on November 28, 2025, at a price of $4.56 per share.
• This transaction represents Dr. Armen's salary for the pay period ending November 28, 2025, paid in stock instead of cash, at his request and with Compensation Committee approval.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
• Following this transaction, Dr. Armen directly owns 298,085 shares of common stock.
• Indirect holdings include 31,298 shares in IRA accounts, 23,950 shares held by the Garo Armen 2020 2 Year AG GRAT, and 5,000 shares held by Pixie Partners (with beneficial ownership disclaimed to the extent of pecuniary interest).

Sentiment

Score: 7

Explanation: The sentiment is positive as the CEO's decision to take salary in stock indicates strong confidence in the company's future and aligns his interests with shareholders. This is generally viewed favorably by the market.

Positives

• The CEO's decision to receive salary in stock demonstrates confidence in the company's future performance and aligns his interests with those of shareholders.
• The shares acquired are fully vested upon issuance, indicating immediate ownership and commitment.

Negatives

• The issuance of new shares, even for compensation, can lead to minor dilution for existing shareholders, though the amount here is small.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the immediate transaction details.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

Stock-based compensation for executives is a common practice across various industries, particularly in biotechnology and growth-oriented companies like Agenus. It serves to align management incentives with shareholder value creation and can also help conserve cash for operational needs or R&D.

Comparison to Industry Standards

• Many biotech and pharmaceutical companies, similar to Agenus, utilize equity compensation plans to attract and retain key executives and scientists. For example, companies like Moderna and BioNTech frequently use stock options and restricted stock units as a significant component of executive pay.
• The practice of executives opting for stock in lieu of cash salary, as seen with Dr. Armen, is a strong signal of confidence, comparable to similar actions taken by leaders at companies such as Tesla (Elon Musk) or MicroStrategy (Michael Saylor) who have publicly committed to significant personal stock holdings.

Related Party Transactions

• The transaction involves the payment of salary to the CEO in company stock, which is an internal compensation arrangement approved by the Compensation Committee.

Stakeholder Impact

• Shareholders: The CEO's increased stock ownership aligns his interests more closely with shareholders, potentially fostering greater long-term value creation. There is a minor dilutive effect from the issuance of new shares, but it is negligible given the amount.
• Employees: The use of stock-based compensation for the CEO may set a precedent or reinforce the company's overall compensation philosophy, potentially impacting employee morale and retention if similar incentives are offered.

Key Dates

Recommendation

This Form 4 filing primarily discloses an executive compensation event rather than a significant operational or financial update. While the CEO's decision to take salary in stock is a positive signal of confidence, it is not a material event that would typically warrant a change in investment recommendation on its own. Investors should 'hold' and consider this as a minor positive data point within their broader analysis of Agenus's fundamentals and strategic direction.

Keywords

Agenus Inc., AGEN, Garo H. Armen, Insider Trading, Form 4, Stock Compensation, Equity Incentive Plan, CEO Stock Purchase, Beneficial Ownership